Table 1.
At Primary Diagnosis | N = 60 | CTC+ (n = 20) | CTC− (n = 37) | p Value |
---|---|---|---|---|
Age (years) | ||||
Mean | 52 | 55 | 49 | 0.0848 |
Range | 28–76 | 39–76 | 28–75 | |
ER | ||||
Positive | 60 | 20 | 37 | - |
PR | ||||
Positive | 54 | 18 | 34 | 0.9411 |
Negative | 6 | 2 | 3 | |
ERBB2 | ||||
Positive | 8 | 2 | 5 | 0.8235 |
Negative | 43 | 15 | 26 | |
Grade | ||||
G1–2 | 29 | 11 | 18 | 0.4656 |
G3 | 10 | 2 | 7 | |
T-stage | ||||
1–2 | 34 | 12 | 21 | 0.7028 |
3–4 | 12 | 3 | 8 | |
N-stage | ||||
0 | 12 | 4 | 7 | 0.9613 |
1–3 | 33 | 11 | 21 | |
initial M-stage | ||||
0 | 13 | 3 | 10 | 0.8683 |
1 | 12 | 2 | 9 | |
At blood draw | N = 97 | CTC+ (n = 31) | CTC− (n = 66) | |
Age (years) | ||||
Mean | 62 | 63 | 62 | 0.8006 |
Range | 34–86 | 39–86 | 34–80 | |
Therapy | ||||
Naïve | 9 | 4 | 5 | 0.5536 |
Endocrine | 37 | 10 | 27 | |
Chemo | 51 | 17 | 34 | |
Stage | ||||
Stable | 37 | 7 | 30 | 0.0476 |
Progression | 38 | 17 | 21 |